03 January 2024
03 January 2024
In 2023, investors pursued pharmaceutical assets with value amidst an unstable economic environment.
The IRP allows the MHRA to leverage the expertise of international regulatory bodies.
The move includes the acquisition of a concussion product, ONP-002, and a nasal delivery device.
BMS filed the application for repotrectinib based on findings from the registrational Phase I/II TRIDENT-1 trial and CARE study.
One of the advantages of these novel ULTs is their superior efficacy and safety profile against their competitors.
Roche will make development, regulatory and commercial milestone payments of $1bn.
Healthcare investment company Patient Square Capital spearheaded the funding round.
The market will also face some challenges such as competition from biosimilars during the period.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
GlobalData's latest thematic report will help you to understand and identify the important themes that threaten to disrupt your business in 2024. Our 2024 theme map covers not only disruptive tech themes but also ESG, macroeconomic, and regulatory themes. Reading this report is the first step towards making better business decisions in 2024.
Give your business an edge with our leading industry insights.
